Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$2.75
-0.9%
$5.93
$2.60
▼
$11.15
$25.78M1.69159,530 shs558,943 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.38
-26.1%
$0.54
$0.24
▼
$2.33
$16.53M0.88662,165 shs529,195 shs
Metagenomi, Inc. stock logo
MGX
Metagenomi
$0.68
-1.7%
$0.95
$0.60
▼
$1.87
$25.71M0.82193,417 shs189,120 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.34
-10.5%
$0.68
$0.34
▼
$9.75
$6.84M-1.54878,199 shs100,953 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.00%-8.85%-39.17%-68.19%-73.77%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.00%+36.96%+19.53%-32.39%-77.36%
Metagenomi, Inc. stock logo
MGX
Metagenomi
0.00%-2.50%-11.77%-43.30%-60.25%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%+0.34%-38.82%-66.20%-95.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$2.75
-0.9%
$5.93
$2.60
▼
$11.15
$25.78M1.69159,530 shs558,943 shs
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
$0.38
-26.1%
$0.54
$0.24
▼
$2.33
$16.53M0.88662,165 shs529,195 shs
Metagenomi, Inc. stock logo
MGX
Metagenomi
$0.68
-1.7%
$0.95
$0.60
▼
$1.87
$25.71M0.82193,417 shs189,120 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.34
-10.5%
$0.68
$0.34
▼
$9.75
$6.84M-1.54878,199 shs100,953 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.00%-8.85%-39.17%-68.19%-73.77%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.00%+36.96%+19.53%-32.39%-77.36%
Metagenomi, Inc. stock logo
MGX
Metagenomi
0.00%-2.50%-11.77%-43.30%-60.25%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
0.00%+0.34%-38.82%-66.20%-95.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
2.89
Moderate Buy$37.801,272.55% Upside
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
2.00
Hold$8.002,005.26% Upside
Metagenomi, Inc. stock logo
MGX
Metagenomi
2.33
Hold$6.00782.35% Upside
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest TPST, ESLA, ACET, and MGX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/28/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
UpgradeSell (E+) ➝ Sell (D-)
10/13/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
DowngradeSell (D-) ➝ Sell (E+)
10/9/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Reiterated RatingSell (E+)
9/29/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Reiterated RatingBuy
9/28/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Reiterated RatingOutperform$25.00 ➝ $28.00
9/28/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Boost Price TargetBuy$27.00 ➝ $34.00
9/24/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
UpgradeSell (E+) ➝ Sell (D-)
9/22/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
DowngradeSell (D-) ➝ Sell (E+)
9/18/2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
Reiterated RatingBuy$27.00
9/9/2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
UpgradeSell (E+) ➝ Sell (D-)
9/8/2026
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
N/AN/AN/AN/A$16.62 per shareN/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/A($0.27) per shareN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
$7.09M3.63N/AN/A$4.22 per share0.16
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$1.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
-$116.80M-$8.57N/AN/AN/AN/A-69.71%-56.97%N/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$13.06M-$0.24N/AN/AN/AN/AN/A-328.72%12/2/2026 (Estimated)
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$87.87M-$2.50N/AN/AN/A-384.61%-75.04%-50.29%N/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$3.70N/AN/AN/AN/A-866.72%-148.66%N/A

Latest TPST, ESLA, ACET, and MGX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/2/2026N/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
-$0.08N/AN/AN/AN/AN/A
11/13/2026Q3 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.32-$0.21+$0.11-$0.21N/AN/A
11/10/2026Q3 2026
Metagenomi, Inc. stock logo
MGX
Metagenomi
-$0.6395-$0.56+$0.0795-$0.56$2.58 million$2.18 million
11/5/2026Q3 2026
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
-$1.56-$1.76-$0.20-$1.76N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$0.041.45%N/AN/A N/A
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/AN/AN/AN/AN/A
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
0.01
6.09
6.09
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
N/A
0.20
0.20
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
3.43
3.43
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
83.89%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
0.35%
Metagenomi, Inc. stock logo
MGX
Metagenomi
N/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
3.40%
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
5.80%
Metagenomi, Inc. stock logo
MGX
Metagenomi
12.50%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
31.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
1029.36 million9.04 millionOptionable
Estrella Immunopharma, Inc. stock logo
ESLA
Estrella Immunopharma
343.50 million40.98 millionNot Optionable
Metagenomi, Inc. stock logo
MGX
Metagenomi
10737.81 million33.08 millionN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
420.00 million13.70 millionNo Data

Recent News About These Companies

Tempest Therapeutics names Nancy Freda-Smith to its board

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adicet Bio stock logo

Adicet Bio NASDAQ:ACET

$2.75 -0.03 (-0.94%)
Closing price 03:59 PM Eastern
Extended Trading
$2.76 +0.01 (+0.40%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

Estrella Immunopharma stock logo

Estrella Immunopharma NASDAQ:ESLA

$0.38 -0.13 (-26.07%)
Closing price 04:00 PM Eastern
Extended Trading
$0.38 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Metagenomi stock logo

Metagenomi NASDAQ:MGX

$0.68 -0.01 (-1.69%)
Closing price 04:00 PM Eastern
Extended Trading
$0.68 0.00 (-0.15%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$0.34 -0.04 (-10.50%)
Closing price 04:00 PM Eastern
Extended Trading
$0.34 +0.00 (+0.94%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.